Cellular Therapy Tracking Market Report 2025

The cellular therapy tracking market size has grown rapidly in recent years. It will grow from $2.56 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be linked to an increase in clinical trials for regenerative medicine, heightened emphasis on personalized medicine, expansion of collaborations between academia and industry, greater awareness of cell therapy effectiveness and safety, and rising investments and venture capital in cell and gene therapy companies.

The cellular therapy tracking market size is expected to see rapid growth in the next few years. It will grow to $4.71 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be linked to wider adoption of personalized and precision medicine, a growing pipeline of cell and gene therapies, an increase in clinical trials and regulatory approvals, higher incidence of chronic and rare diseases, and expansion of cell therapy manufacturing capabilities. Key trends during the forecast period include integration of cell therapy tracking with digital health platforms, use of bioinformatics in cellular research, advancements in cellular therapy studies, enhanced regulatory-compliance tools, and implementation of AI and machine learning.

The growth of the cellular therapy tracking market is being driven by the increasing use of personalized medicine, particularly due to the growing demand for patient-specific cell monitoring and adherence to regulatory standards. Personalized medicine is an approach that customizes treatment and prevention based on an individual’s genetic profile, lifestyle, and environment. This shift is largely fueled by advancements in genomics, which allow for the precise identification of genetic variations and the creation of tailored treatments. Cellular therapy tracking plays a vital role in supporting personalized medicine by ensuring accurate monitoring and management of patient-specific cells throughout therapy. It enhances both the safety and effectiveness of treatments by offering traceability, regulatory compliance, and an efficient workflow for healthcare providers. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, compared to 12 in 2022. This increase in personalized medicine adoption is propelling the growth of the cellular therapy tracking market.

Key players in the cellular therapy tracking market are focusing on creating scalable platforms, such as chain of identity (COI) management systems, to ensure traceability, regulatory compliance, and patient safety. These COI management platforms are digital systems that track and verify the identity of patient-specific cells throughout the entire therapy process. For example, in May 2023, TrakCel Limited, a UK-based software company, launched OCELLOS Core, part of its OCELLOS suite, designed as a COI management platform for early-stage autologous and personalized cell and gene therapy (CGT) clinical trials. This platform offers automated COI tracking, ensuring accurate patient records from the initial enrollment. The system is pre-configured and validated, allowing deployment within two to three weeks and offering cost-effective scalability as therapies progress from clinical trials to commercialization. It also tracks chain of custody events with full audit trails, improving compliance and collaboration.

In June 2025, STEMCELL Technologies Inc., a biotechnology company based in Canada, acquired Cellular Highways Ltd. for an undisclosed amount. This acquisition allows STEMCELL Technologies to integrate Cellular Highways' advanced cell sorting technology into its offerings, enhancing the precision, scalability, and efficiency of cellular therapy manufacturing and tracking. Cellular Highways Ltd., a UK-based biotechnology firm, specializes in innovative cell sorting technologies for cellular therapy tracking.

Major players in the cellular therapy tracking market are Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Gilead Sciences Inc., Merck KGaA, GE Healthcare Technologies Inc., Becton Dickinson and Company, Lonza Group Ltd., Nikon Corporation, Charles River Laboratories International Inc., Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Vericel Corporation, Adaptimmune Therapeutics plc, Medipost Co. Ltd., and TrakCel.

North America was the largest region in the cellular therapy tracking market in 2024. The regions covered in cellular therapy tracking report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cellular therapy tracking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cellular therapy tracking refers to the organized process of overseeing and managing the full lifecycle of cellular therapies, including cell collection, production, distribution, administration, and long-term patient monitoring. It maintains product quality, regulatory adherence, patient safety, and treatment success through comprehensive data recording and traceability. It also supports workflow optimization and ensures precise documentation throughout the therapy process.

The primary product categories in cellular therapy tracking are software and services. The software delivers digital platforms and tools to handle, observe, and organize information related to cell therapy activities and procedures. It is applied in areas such as cancer, cardiovascular conditions, musculoskeletal disorders, and more, serving end users including hospitals, research institutions, biotechnology companies, and others.

The cellular therapy tracking market research report is one of a series of new reports that provides cellular therapy tracking market statistics, including the cellular therapy tracking industry global market size, regional shares, competitors with the cellular therapy tracking market share, detailed cellular therapy tracking market segments, market trends, and opportunities, and any further data you may need to thrive in the cellular therapy tracking industry. This cellular therapy tracking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cellular therapy tracking market includes revenues earned by entities through logistics management, temperature-controlled shipping, chain of custody compliance, consulting and advisory support, cryopreservation, secure biostorage, end-to-end supply chain solutions, and quality assurance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.